CytomX Therapeutics, Inc.

NasdaqGS:CTMX Rapporto sulle azioni

Cap. di mercato: US$96.1m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CytomX Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 3/6

CytomX Therapeutics ha un patrimonio netto totale di $-31.2M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $159.2M e $190.4M. L'EBIT di CytomX Therapeutics è $5.7M rendendo il suo rapporto di copertura degli interessi -0.6. Ha liquidità e investimenti a breve termine pari a $137.2M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi-0.6x
ContantiUS$137.18m
Patrimonio netto-US$31.23m
Totale passivitàUS$190.45m
Totale attivitàUS$159.22m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Checking In On CytomX Therapeutics

Jun 13

Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Jun 10
Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Analisi della posizione finanziaria

Passività a breve termine: CTMX ha un patrimonio netto negativo, che è una situazione più grave rispetto a quella delle attività a breve termine che non coprono le passività a breve termine.

Passività a lungo termine: CTMX ha un patrimonio netto negativo, il che rappresenta una situazione più grave rispetto a quella delle attività a breve termine che non coprono le passività a lungo termine.


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: CTMX è esente da debiti.

Riduzione del debito: CTMX ha un patrimonio netto negativo, quindi non abbiamo bisogno di controllare se il suo debito si è ridotto nel tempo.

Copertura del debito: CTMX non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: CTMX non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.


Bilancio


Scoprire le aziende sane